Patients with follicular lymphoma (FL) grade (G) 1-3A who meet treatment criteria are commonly treated with chemo-immunotherapy regimens such as bendamustine plus rituximab (BR) or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP). Two prospective trials have compared BR to RCHOP-like regimens and showed improved progression free survival with BR in FL G1-2 patients. However, in real-world practice, there is clinical variability in utilization of BR versus RCHOP-like regimens. Additionally, the optimal treatment for patients with FL G3A remains unclear. We used a nationwide electronic health record-derived de-identified database to compare outcomes in 2089 patients with FL G1-3A treated with frontline BR versus RCHOP-like regimens. We demonstrated clinical improvement in time to next treatment or death (TTNTD) with BR (median 96 vs. 78 months, HR 1.15, 95% CI 0.986-1.332, P = .086), albeit not statistically significant. No difference in overall survival (OS) was observed. Maintenance rituximab was associated with improved TTNTD and OS. Among G3A patients (N = 304), TTNTD was comparable between the 2 regimens, however OS was significantly improved with RCHOP-like regimens in univariate analysis (median 138 vs. 96 months, HR 0.51, 95% CI 0.313-0.834, P = .007). In conclusion, this study of real-world patients supports the use of BR and rituximab maintenance for front-line treatment of FL. Further prospective studies are needed to determine the ideal treatment for FL G3A.
Introduction: Gastrointestinal (GI) follicular lymphoma (FL) is a rare disease, accounting for less than 5% of GI non‐Hodgkin's lymphomas (NHL). We conducted a multi‐institutional study to clarify baseline features, common practices, and survival outcomes in primary GI FL. Methods: We performed a retrospective analysis of patients with primary GI FL from 8 North American institutions. Progression‐free survival (PFS), overall survival (OS), and progression of disease at 24 months (POD24) were assessed. Results: Two hundred and two patients were included in the analysis. Median follow up was 5.6 years. Median age at diagnosis was 60 years (range: 51–68) with a 1:1 male to female ratio. For those observed, median time to first treatment was 4.5 years. For those treated, overall response rate was 93% ( n = 112) and median time to second‐line treatment was 3.9 years. Patients who were initially observed had similar OS to those who were treated up‐front. Age ≥ 60, histologic Grade 3A, and hemoglobin < 12 g/dL at diagnosis were independent predictors of inferior survival. Based on these results, we created the GI‐FLIPI score, a prognostic index using these three readily available clinical factors to help predict outcomes in patients with GI FL. Median OS was significantly shorter in the high‐risk group compared to intermediate‐ and low‐risk groups, with a c‐index of 0.767. Conclusions: This multi‐institutional analysis describes characteristics of a large cohort of patients with GI FL. The GI‐FLIPI score shows promise with high prediction accuracy and may help guide management in the future.
Autoimmune diseases (AIDs) have been shown to be a risk factor for the development of non-Hodgkin lymphoma (NHL), with more than 15 million Americans diagnosed with AIDs between 2011 and 2022